Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011–2014)

• Published in: European journal of clinical microbiology & infectious diseases Vol. 36; no. 6; pp. 1013 - 1017
• Main Authors: Mendes, R. E., Sader, H. S., Smart, J. I., Castanheira, M., Flamm, R. K.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2017; Springer Nature B.V
• Subjects: Aminoglycosides - pharmacology; Anti-Bacterial Agents - pharmacology; Antibiotics; Bacteremia; Bacteremia - microbiology; Biomedical and Life Sciences; Biomedicine; Clinical isolates; Collection; Demographics; Endocarditis; Endocarditis, Bacterial - microbiology; Global Health; Gram-positive bacteria; Humans; In vitro methods and tests; Internal Medicine; Medical Microbiology; Methicillin; Microbial Sensitivity Tests; Minimum inhibitory concentration; Multidrug resistance; Original; Original Article; Public health; Staphylococcal Infections - microbiology; Staphylococcus aureus; Staphylococcus aureus - drug effects; Staphylococcus aureus - isolation & purification; Staphylococcus infections; Vancomycin; Minimum Inhibitory Concentration; Oxacillin; Broth Microdilution; Endocarditis; Daptomycin

The efficacy and safety of telavancin is under evaluation for the treatment of subjects with complicated Staphylococcus aureus bacteremia and S. aureus right-sided infective endocarditis. This study evaluated the telavancin activity against a global collection of S. aureus causing bloodstream infect...